证券代码：300677 证券简称：英科医疗 公告编号：2024-088 英科医疗科技股份有限公司 | | | 份，无标记股份；"未质押股份限售和冻结数量"中限售部分为高管锁定股，无冻结股份。 三、其他说明 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于近日接到公 司控股股东刘方毅先生的通知，获悉刘方毅先生将其所持有的公司部 分股份办理了解除质押手续。现将具体内容公告如下： 注：本公告总股本数以截至 2024 年 8 月 28 日公司最新总股本 647,901,380 股为计算标准。 二、股东股份累计质押的情况 截至本公告披露日，刘方毅先生所持质押股份情况如下： | | | | | | | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 占其所 | 占公司 | 已质押股份 | | | | | 股东 | 持股数量 | 持股比 | 累计质押数 | ...

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Views - The company's revenue for the first half of 2024 reached 4.512 billion RMB, a year-on-year increase of 37%, with a net profit of 587 million RMB, up 100% year-on-year [2] - The disposable glove business is experiencing rapid growth, with a significant increase in sales of nitrile gloves, contributing to a gross margin improvement [2] - The company is expanding its production capacity, with an annual capacity of 79 billion gloves, including 48 billion nitrile gloves, positioning it as a leader in the industry [2] Summary by Sections Performance Overview - In Q2 2024, the company achieved revenue of 2.309 billion RMB, a 34% increase year-on-year and a 5% increase quarter-on-quarter [2] - The gross margin for Q2 2024 was 23.1%, reflecting a 2.4 percentage point increase from the previous quarter and a 9.7 percentage point increase year-on-year [2] Business Analysis - The personal protective equipment segment generated 4.112 billion RMB in revenue, up 39% year-on-year, while rehabilitation and nursing products contributed 233 million RMB, a 30% increase [2] - The company is implementing technological upgrades in production lines to enhance efficiency and reduce energy consumption, further improving profitability [2] Capacity and Expansion - The company is steadily advancing its domestic and international production base construction, with the domestic base in Anhui and an overseas project in Vietnam [2] - The annual production capacity for disposable gloves is 79 billion units, with 48 billion units for nitrile gloves and 31 billion units for PVC gloves [2] Profit Forecast and Valuation - The earnings forecast for 2024-2026 has been raised by 19%, 26%, and 28% respectively, with projected net profits of 1.216 billion, 1.552 billion, and 1.880 billion RMB [2] - The current price corresponds to a PE ratio of 14, 11, and 9 for the years 2024, 2025, and 2026 respectively [2]

Investment Rating - The report maintains a "Buy" rating for the company [3] Core Views - The company has shown significant growth in its financial performance, with a 36.94% year-on-year increase in revenue for the first half of 2024, reaching 4.512 billion yuan, and a remarkable 100.24% increase in net profit, amounting to 587 million yuan [3][4] - The company is positioned as a leader in the glove industry, benefiting from cost advantages and technological upgrades, which enhance production efficiency and reduce costs [3][4] - The report anticipates a recovery in demand and an increase in orders for the company's gloves, projecting a notable growth in revenue and net profit for the upcoming years [7] Financial Performance Summary - In the first half of 2024, the company achieved a revenue of 4.512 billion yuan, with a net profit of 587 million yuan, reflecting a 100.24% increase year-on-year [3] - The first quarter of 2024 saw a revenue of 2.203 billion yuan, a quarter-on-quarter growth of 17.39%, while the second quarter recorded a revenue of 2.309 billion yuan, with a quarter-on-quarter growth of 4.81% [3] - The company’s product categories showed strong performance, with personal protective equipment revenue reaching 4.111 billion yuan, a 38.74% increase year-on-year [4] Production Capacity and Efficiency - The company has increased its annual production capacity of disposable gloves from 75 billion to 79 billion units, with specific capacities of 48 billion for nitrile gloves and 31 billion for PVC gloves [4] - Continuous upgrades in production technology and equipment have led to improved production line speeds and efficiency, contributing to cost reduction [4] Market Strategy and Brand Development - The company is enhancing its global marketing network and increasing investment in online sales channels, with over 400 marketing personnel to support market share growth [4][5] - There is a focus on brand building through traditional and new media to expand brand influence and capture user mindshare [5] Future Outlook - The company plans to continue expanding its production capacity and efficiency in 2024, with ongoing projects in various locations [6] - Revenue forecasts for 2024-2026 are optimistic, with expected revenues of 9.232 billion yuan in 2024, 10.730 billion yuan in 2025, and 12.545 billion yuan in 2026, reflecting growth rates of 33.43%, 16.23%, and 16.92% respectively [7][9]

证券代码：300677 证券简称：英科医疗 公告编号：2024-087 英科医疗科技股份有限公司 关于召开公司 2024 年第三次临时股东大会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2024 年 8 月 28 日召开第三届董事会第二十四次（定期）会议，审议通过了《关 于召开公司 2024 年第三次临时股东大会的议案》，公司决定于 2024 年 9 月 19 日（星期四）14:00 召开公司 2024 年第三次临时股东大会。 现将会议相关事项通知如下： （1）现场会议召开时间：2024 年 9 月 19 日（星期四）14:00 （2）网络投票时间：2024 年 9 月 19 日。其中，通过深圳证券交 易所交易系统进行网络投票的时间为 2024 年 9 月 19 日 9:15-9:25， 9:30-11:30 和 13:00-15:00；通过深圳证券交易所互联网系统投票的具 体时间为 2024 年 9 月 19 日 9:15-15:00。 5、会议召开方式：采取现场投票和网络投票相结合的方式，公 司将通过深 ...

证券代码：300677 证券简称：英科医疗 公告编号：2024-081 英科医疗科技股份有限公司 关于为子公司提供担保事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日、2024 年 5 月 16 日分别召开的第三届董事会第二十一次（定 期）会议、第三届监事会第十九次（定期）会议以及 2023 年度股东 大会，审议通过了《关于公司及子公司向银行申请授信额度及担保事 项的议案》。为满足公司及子公司的生产经营需要，公司及子公司拟 向银行等金融机构申请综合授信的额度以及金融衍生品交易风险限 额的总额（以下简称"授信额度"）不超过 300 亿元人民币，对其担 保总额不超过 300 亿元人民币，授权期限自公司 2023 年度股东大会 审议通过之日起至下一年度股东大会召开时止。具体内容详见刊登于 巨潮资讯网（www.cninfo.com.cn）的《关于公司及子公司向银行申请 授信额度及担保事项的公告》《2023 年度股东大会决议公告》（公告 编号：2024-036、2024-050 ...

Investment Rating - The report assigns a "Buy" rating for the company, with a target price of 25.94 CNY per share [1][3]. Core Insights - The report indicates that the disposable glove industry is at a turning point after experiencing inventory destocking and overcapacity, with multiple factors suggesting a recovery in supply-demand balance [1][3]. - The company, Yingke Medical, has a significant production capacity of 79 billion gloves, ranking second globally, and is expected to benefit from cost, capacity, and financial advantages [1][3][11]. - The report highlights that Chinese manufacturers have gained market share due to advantages in energy costs, production efficiency, and supply chain support compared to Malaysian competitors [1][3][11]. Summary by Sections Company Overview - Yingke Medical was established in 2009 and has rapidly expanded its disposable glove production capacity from 36 billion in 2020 to 79 billion by the end of 2023 [11]. - The company has five major production bases in China and exports to over 120 countries and regions [11]. Industry Analysis - The disposable glove market has seen a surge in demand due to the pandemic, followed by a phase of destocking and overcapacity, with signs indicating that the turning point has been reached [1][18]. - The report notes that nitrile gloves are expected to become the mainstream product in the disposable glove market, with their market share projected to increase from 35.2% to 37.1% by 2025 [21]. Financial Performance and Forecast - The company reported a revenue of 6.919 billion CNY in 2023, with a projected revenue of 9.099 billion CNY for 2024, reflecting a year-on-year growth of 31.5% [5][3]. - The forecast for net profit for 2024 is 1.283 billion CNY, with an expected EPS of 1.98 CNY, indicating a significant recovery from previous years [5][3]. Competitive Advantages - The company has a robust financial position, with cash and tradable financial assets amounting to 151.38 million CNY as of Q1 2024, allowing it to navigate potential tariff impacts effectively [2][3]. - Yingke Medical's cost control measures, including upstream integration and energy self-supply, are expected to enhance its competitive edge [1][3][2].

| 证券代码：300677 证券简称：英科医疗 | 公告编号：2024-079 | | --- | --- | | 债券代码：123029 债券简称：英科转债 | | 7. 下一付息期起息日：2024 年 8 月 16 日 英科医疗科技股份有限公司 关于英科转债 2024 年付息公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 1. 英科转债（债券代码：123029）将于 2024 年 8 月 16 日按面 值支付第五年利息，每 10 张英科转债（面值 1,000.00 元）利息为 35.00 元（含税）。 2. 债权登记日：2024 年 8 月 15 日 3. 本次付息期间及票面利率：计息期间为 2023 年 8 月 16 日至 2024 年 8 月 15 日，票面利率为 3.5%。 4. 付息日：2024 年 8 月 16 日 5. 除息日：2024 年 8 月 16 日 6. 本次付息的债权登记日为 2024 年 8 月 15 日，凡在 2024 年 8 月 15 日（含）前买入并持有本期债券的投资者享有本次派发的利息。 英科医疗科技股份有限公 ...

证券代码：300677 证券简称：英科医疗 公告编号：2024-080 英科医疗科技股份有限公司 关于为子公司提供担保事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日、2024 年 5 月 16 日分别召开的第三届董事会第二十一次（定 期）会议、第三届监事会第十九次（定期）会议以及 2023 年度股东 大会，审议通过了《关于公司及子公司向银行申请授信额度及担保事 项的议案》。为满足公司及子公司的生产经营需要，公司及子公司拟 向银行等金融机构申请综合授信的额度以及金融衍生品交易风险限 额的总额（以下简称"授信额度"）不超过 300 亿元人民币，对其担 保总额不超过 300 亿元人民币，授权期限自公司 2023 年度股东大会 审议通过之日起至下一年度股东大会召开时止。具体内容详见刊登于 巨潮资讯网（www.cninfo.com.cn）的《关于公司及子公司向银行申请 授信额度及担保事项的公告》《2023 年度股东大会决议公告》（公告 编号：2024-036、2024-050 ...

Investment Rating - The report maintains a "Buy" rating for the company [2]. Core Views - The company is the largest disposable glove supplier in China and globally, focusing on medical consumables, rehabilitation equipment, and physiotherapy care, with personal protective equipment accounting for 89% of its revenue [2][12]. - The company is expected to experience significant revenue growth from 2024 to 2026, with projected revenues of 8.545 billion yuan, 9.776 billion yuan, and 11.753 billion yuan, representing year-on-year growth rates of 24%, 14%, and 20% respectively [2][7]. - The company’s net profit is projected to increase significantly, with expected figures of 1.293 billion yuan, 1.692 billion yuan, and 2.182 billion yuan for the same period, reflecting year-on-year growth rates of 238%, 31%, and 29% respectively [2][7]. Summary by Sections Company Overview - The company was established in 1993 and has become a leading disposable glove supplier globally, serving over 10,000 clients across more than 120 countries [12]. - The company’s first major shareholder, Liu Fangyi, has extensive industry experience and has been instrumental in the company's growth [12][14]. Market Dynamics - The disposable glove industry is recovering from a period of oversupply, with expectations for a turnaround in 2024 as inventory levels normalize [2][16]. - The average export price of nitrile gloves has stabilized, with a 26% month-on-month increase in export volume noted in June 2024 [3][20]. Financial Performance - The company reported a revenue of 6.919 billion yuan in 2023, a 4.61% increase year-on-year, but faced a net profit decline of 39.12% due to market conditions [12][16]. - In Q1 2024, the company achieved a revenue of 2.203 billion yuan, a 40.06% increase year-on-year, and a net profit of 238 million yuan, reflecting a 255.63% increase [12][15]. Competitive Advantages - The company maintains a high gross margin in the nitrile and PVC glove segments, benefiting from upstream control of raw materials and energy cost advantages [4][16]. - The company is expanding its global customer base and enhancing brand visibility to mitigate the impact of tariffs and market fluctuations [5][16]. Future Outlook - The global market for disposable gloves is projected to grow, with an expected CAGR of 7.8% from 2019 to 2025, particularly in the nitrile glove segment [19][20]. - The company is well-positioned to capitalize on this growth, with a focus on innovation and cost control strategies [4][16].

上海泽昌律师事务所 法律意见书 上海泽昌律师事务所 关于英科医疗科技股份有限公司 2024年第二次临时股东大会的 法律意见书 上海市浦东新区世纪大道 1589 号长泰国际金融大厦 11 层 邮编：200120 电话：021-61913137 传真：021-61913139 二零二四年八月 上海泽昌律师事务所 法律意见书 上海泽昌律师事务所 关于英科医疗科技股份有限公司 2024 年第二次临时股东大会的 法律意见书 泽昌证字 2024-01-03-04 致：英科医疗科技股份有限公司 本所接受英科医疗科技股份有限公司（以下简称"公司"）委托，就公司召 开 2024 年第二次临时股东大会（以下简称"本次股东大会"）的有关事宜，根 据《中华人民共和国公司法》（以下简称《公司法》）、《上市公司股东大会规 则》等法律、法规、规章和其他规范性文件以及《英科医疗科技股份有限公司章 程》（以下简称《公司章程》）的有关规定，出具本法律意见书。 上海泽昌律师事务所 法律意见书 本次股东大会现场会议于 2024 年 8 月 7 日在公司会议室如期召开。网络投 票时间为 2024 年 8 月 7 日，其中，通过深圳证券交易所交易系统进 ...